Finanzen von Jyong Biotech Ltd (MENS)MENSJyong Biotech Ltd

In the context of the broader market, MENS competes directly with industry leaders such as LFCR and MDWD. With a market capitalization of $180.19M, it holds a leading position in the sector. When comparing efficiency, MENS's gross margin of N/A stands against LFCR's 35.34% and MDWD's 10.90%. Such benchmarking helps identify whether Jyong Biotech Ltd is trading at a premium or discount relative to its financial performance.

The company's financial performance shows a negative EPS forecast for 2025, with estimates of -0.06 for Q4, and a current ratio of only 0.02 in Q4 2024, indicating liquidity issues. Total equity remains negative at -36,519,000 USD.